Inotiv Inc
NASDAQ:NOTV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Inotiv Inc
Total Equity
Inotiv Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inotiv Inc
NASDAQ:NOTV
|
Total Equity
$109m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
71%
|
CAGR 10-Years
27%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Equity
$53.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Equity
$52.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Waters Corp
NYSE:WAT
|
Total Equity
$2.6B
|
CAGR 3-Years
72%
|
CAGR 5-Years
62%
|
CAGR 10-Years
2%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Equity
$6.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Equity
$6.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Inotiv Inc
Glance View
Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The company is headquartered in West Lafayette, Indiana and currently employs 541 full-time employees. The firm focuses on providing drug developers with scientific research and analytical instrumentation. The firm operates through two segments, including Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance and quality control testing. The Research Products segment offers two principal product lines, including analytical products and in vivo sampling products. Analytical products consist of liquid chromatographic and electrochemical instruments with associated accessories. In vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments.
See Also
What is Inotiv Inc's Total Equity?
Total Equity
109m
USD
Based on the financial report for Dec 31, 2025, Inotiv Inc's Total Equity amounts to 109m USD.
What is Inotiv Inc's Total Equity growth rate?
Total Equity CAGR 10Y
27%
Over the last year, the Total Equity growth was -36%. The average annual Total Equity growth rates for Inotiv Inc have been -27% over the past three years , 71% over the past five years , and 27% over the past ten years .
